



Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S.

14th U.S. AI patent awarded complementing a comprehensive portfolio of AI-related intellectual property

An ecosystem built around the Cellvizio® platform, enabling partners to develop advanced AI models

Paris and Boston, July 21, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that it has been granted the 14th U.S. patent¹ for real-time AI-based enhancement of Confocal Laser Endomicroscopy (CLE) image sequences, continuing to expand its intellectual property portfolio in the field of artificial intelligence.

With this new technological asset, which focuses on the cognitive interface between doctors and machines, Mauna Kea Technologies is reinforcing its position at the heart of all rapid developments in centers of excellence in AI applied to Cellvizio imaging.

This latest milestone builds upon the Company's recent advancements, including the previously announced major AI breakthrough with Cellvizio for risk stratification of malignant pancreatic cystic lesions. By strengthening its platform's core technology, Mauna Kea Technologies is positioning itself as an essential partner and catalyst for the entire AI research and development ecosystem, enabling third parties to build high-value applications on the Cellvizio platform.

Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies commented: *"This 14th patent is perfectly aligned with our strategy of building the technological backbone for an AI-powered Cellvizio ecosystem. By enhancing the critical physician-machine interface, this patent further strengthens Cellvizio as a powerful and intuitive foundation for our partners, present and future."*

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.

¹ Filing number US-D1082842



Mauna Kea Technologies

investors@maunakeatech.com

NewCap - Investor Relations

Aurélie Manavarere / Thomas Grojean

+33 (0)1 44 71 94 94

maunakea@newcap.eu

Disclaimer

This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the *Autorité des marchés financiers* (AMF) on April 30, 2025, which is available on the Company's website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.